PT  - JOURNAL ARTICLE
AU  - Jacobson, Anne
ED  - Yusuf, Salim
TI  - Irbesartan Fails to Prevent Most Vascular Events in Patients with AF
DP  - 2009 Dec 01
TA  - MD Conference Express
PG  - 12--13
VI  - 9
IP  - 4
4099  - http://mdc.sagepub.com/content/9/4/12.2.short
4100  - http://mdc.sagepub.com/content/9/4/12.2.full
AB  - In the Atrial Fibrillation Clopidogrel Trial with Irbesartan for Prevention of Vascular Events [ACTIVE-I; NCT00249795], treatment with irbesartan failed to lower the risk of stroke, myocardial infarction, and vascular death compared with placebo in patients with atrial fibrillation (AF). However, irbesartan may have a role in preventing heart failure, recurrent embolic events, and cardiovascular hospitalizations in patients with AF.